Alloy Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 137

Employees

  • Latest Deal Type
  • Series E

  • Latest Deal Amount
  • $40M

  • Investors
  • 25

Alloy Therapeutics General Information

Description

Developer of a product development platform designed to help biotechnology companies, pharmaceutical organizations, academic founders, and sovereign institutions discover and develop medicines. The company's platform offers proprietary technology, artificial intelligence, real-world data, and integrated capabilities across antibody and multispecific development, TCR mimics, genetic medicines, cell therapies, pharmacology, and clinical development, enabling partner-owned drug programs to progress from early research toward clinical development and commercialization.

Contact Information

Website
www.alloytx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 275 Second Avenue
  • Suite 200
  • Waltham, MA 02451
  • United States
+1 (617)
Primary Industry
Discovery Tools (Healthcare)
Corporate Office
  • 275 Second Avenue
  • Suite 200
  • Waltham, MA 02451
  • United States
+1 (617)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Alloy Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series E) 31-Mar-2026 $40M Completed Generating Revenue
6. Later Stage VC (Series D) 16-Sep-2022 Completed Generating Revenue
5. Grant 01-Jun-2021 Completed Generating Revenue
4. Later Stage VC (Series C) 02-Apr-2021 Completed Generating Revenue
3. Early Stage VC (Series B) 10-May-2020 Completed Generating Revenue
2. Early Stage VC (Series A1) 15-May-2019 $6M $6M Completed Generating Revenue
1. Accelerator/Incubator Completed Generating Revenue
To view Alloy Therapeutics’s complete valuation and funding history, request access »

Alloy Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series E2
Series E1
Series D
Series C
Series B
Series A3
Series A2 1,949,906 $0.000100 $0.77 $0.77 1x $0.77 5.1%
Series A1 1,444,374 $0.000100 $0.35 $0.35 1x $0.35 3.78%
To view Alloy Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Alloy Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a product development platform designed to help biotechnology companies, pharmaceutical organizations, acad
Discovery Tools (Healthcare)
Waltham, MA
137 As of 2026

San Diego, CA
 

Poway, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Alloy Therapeutics Competitors (30)

One of Alloy Therapeutics’s 30 competitors is BioLegend, a Formerly Accelerator/Incubator backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BioLegend Formerly Accelerator/Incubator backed San Diego, CA
ProSci (Biotechnology) Private Equity-Backed Poway, CA
Abcam Corporate Backed or Acquired Cambridge, United Kingdom
Creative Biolabs Corporation Shirley, NY
Regis Technologies Formerly VC-backed Morton Grove, IL
You’re viewing 5 of 30 competitors. Get the full list »

Alloy Therapeutics Patents

Alloy Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026174257-A1 Production of anitgen-reactive vl antibodies in vivo Pending 13-Feb-2025
WO-2026170086-A1 Anti-transferrin receptor 1 (anti-tfr1) antibodies, compositions, and methods for use in tfr1-mediated delivery of therapeutic payloads Pending 08-Feb-2025
WO-2026055339-A1 Methods for identifying cognate immunoglobulin pairs from individual b cells Pending 04-Sep-2024
WO-2026006494-A1 Anti-cd3 antibodies and uses thereof Pending 25-Jun-2024
WO-2026006496-A1 Anti-cd3 antibodies and uses thereof Pending 25-Jun-2024 C07K16/2809
To view Alloy Therapeutics’s complete patent history, request access »

Alloy Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Alloy Therapeutics Investors (25)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alumni Ventures Venture Capital Minority
Echo Capital PE/Buyout Minority
JIC Venture Growth Investments Venture Capital Minority
Germin8 Ventures Venture Capital Minority
Mubadala Capital Asset Manager Minority
You’re viewing 5 of 25 investors. Get the full list »

Alloy Therapeutics Investments & Acquisitions (15)

Alloy Therapeutics’s most recent deal was a Joint Venture with Developing Antibody Drug (Alloy Therapeutics / Tahoe). The deal was made on 13-Jan-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Developing Antibody Drug (Alloy Therapeutics / Tahoe) 13-Jan-2026 Joint Venture Drug Discovery
Spannerwerks, An Alloy Therapeutics Company 15-Oct-2025 Merger/Acquisition Biotechnology
Wheeler Bio 20-Mar-2025 Later Stage VC Biotechnology
Aakha Biologics 15-Apr-2024 Seed Round Drug Discovery
Cantai Therapeutics 20-Nov-2023 Seed Round Drug Discovery
You’re viewing 5 of 15 investments and acquisitions. Get the full list »

Alloy Therapeutics Affiliates

Subsidiaries (3)

Name Industry Location Year Founded
Spannerwerks, An Alloy Therapeutics Company Seattle, WA 2015
Lanier Biotherapeutics Jefferson, GA 2000
82VS Boston, MA

Alloy Therapeutics FAQs

  • When was Alloy Therapeutics founded?

    Alloy Therapeutics was founded in 2017.

  • Where is Alloy Therapeutics headquartered?

    Alloy Therapeutics is headquartered in Waltham, MA.

  • What is the size of Alloy Therapeutics?

    Alloy Therapeutics has 137 total employees.

  • What industry is Alloy Therapeutics in?

    Alloy Therapeutics’s primary industry is Discovery Tools (Healthcare).

  • Is Alloy Therapeutics a private or public company?

    Alloy Therapeutics is a Private company.

  • What is the current valuation of Alloy Therapeutics?

    The current valuation of Alloy Therapeutics is .

  • What is Alloy Therapeutics’s current revenue?

    The current revenue for Alloy Therapeutics is .

  • How much funding has Alloy Therapeutics raised over time?

    Alloy Therapeutics has raised $174M.

  • Who are Alloy Therapeutics’s investors?

    Alumni Ventures, Echo Capital, JIC Venture Growth Investments, Germin8 Ventures, and Mubadala Capital are 5 of 25 investors who have invested in Alloy Therapeutics.

  • Who are Alloy Therapeutics’s competitors?

    BioLegend, ProSci (Biotechnology), Abcam, Creative Biolabs, and Regis Technologies are some of the 30 competitors of Alloy Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process